Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 5:57 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1729–1752 of 33,121 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: PLACEBO Clear all
Completed Not applicable Interventional Accepts healthy volunteers

A Pilot Study to Determine the Effect of a Cobiotic Formulation on the Gastrointestinal Microbiome

NCT01724736
View directory record Official record
Conditions
Pre Diabetic
Interventions
Placebo, NM504:
Drug
Lead sponsor
NuMe Health
Industry
Eligibility
18 Years to 70 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Nov 1, 2026, 5:57 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Casinomacropeptide and Satiety

NCT01587911
View directory record Official record
Conditions
Lack of Satiety, Excess Intake of Macronutrients, Appetite Disorders
Interventions
Whey, Whey-CMP, Control, CMP, MPI, CPI
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2015
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Aug 14, 2017 · Synced Nov 1, 2026, 5:57 PM EST
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of X0002 Spray in Subjects With Osteoarthritis

NCT02067611
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
X0002, Placebo
Drug
Lead sponsor
Lina Xu
Industry
Eligibility
35 Years to 85 Years
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
20
States / cities
Tempe, Arizona • Carmichael, California • Spring Valley, California + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Nov 1, 2026, 5:57 PM EST
Recruiting Phase 1Phase 2 Interventional

Phase 2 Trial of Tributyrin in People With Parkinson's Disease and Cognitive Impairments

NCT07154511
View directory record Official record
Conditions
Parkinson Disease, Parkinson Disease Dementia
Interventions
Tributyrin, Placebo
Drug
Lead sponsor
Prabesh Kanel
Other
Eligibility
45 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Nov 1, 2026, 5:57 PM EST
Completed Phase 3 Interventional

Safety and Efficacy of Probuphine in the Treatment of Opioid Dependence

NCT00447564
View directory record Official record
Conditions
Opioid Dependence
Interventions
Probuphine, placebo
Drug
Lead sponsor
Titan Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
18
States / cities
Los Angeles, California • National City, California • Oceanside, California + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2018 · Synced Nov 1, 2026, 5:57 PM EST
Completed Phase 2 Interventional Results available

A Study to Investigate the Efficacy, Safety, and Tolerability of JNJ-42165279 in Adolescent and Adult Participants With Autism Spectrum Disorder

NCT03664232
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
JNJ-42165279, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
13 Years to 35 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
9
States / cities
Dothan, Alabama • Phoenix, Arizona • Orange, California + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Nov 1, 2026, 5:57 PM EST
Completed Phase 2 Interventional

GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection

NCT01434498
View directory record Official record
Conditions
Chronic Genotype 1a or 1b HCV Infection
Interventions
GS-5885 tablet, GS-9451 tablet, tegobuvir capsule, ribavirin tablet, placebo matching ribavirin tablet, placebo matching tegobuvir capsule
Drug · Device
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
36
States / cities
Beverly Hills, California • Coronado, California • La Jolla, California + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2013 · Synced Nov 1, 2026, 5:57 PM EST
Terminated Phase 3 Interventional Results available

Study to Determine if a New Nicotine Replacement Therapy Can Safely Help Smokers to Quit Smoking

NCT01296698
View directory record Official record
Conditions
Tobacco Dependence
Interventions
Placebo, Nicotine
Drug
Lead sponsor
McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.
Industry
Eligibility
18 Years and older
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
19
States / cities
Muscle Shoals, Alabama • Oceanside, California • Griffin, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2012 · Synced Nov 1, 2026, 5:57 PM EST
Not listed No phase listed Observational Accepts healthy volunteers

Neuroscience of Alcohol and Marijuana Impaired Driving

NCT03431987
View directory record Official record
Conditions
Marijuana Usage, Alcohol Drinking
Interventions
One day with a dose of placebo cannabis paired with alcohol, One day with a dose of active THC cannabis paired with alcohol
Drug
Lead sponsor
Hartford Hospital
Other
Eligibility
21 Years to 40 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 5, 2022 · Synced Nov 1, 2026, 5:57 PM EST
Terminated Phase 1Phase 2 Interventional Results available

Hypertrophic Scar Prevention by Novel Topical Gel Application

NCT03403621
View directory record Official record
Conditions
Hypertrophic Scar
Interventions
Pentamidine Isethionate, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 22, 2023 · Synced Nov 1, 2026, 5:57 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Protein and Recovery From Exercise-induced Muscle Damage

NCT02034721
View directory record Official record
Conditions
Muscle Damage, Inflammation
Interventions
Protein supplement, Placebo
Dietary Supplement
Lead sponsor
Appalachian State University
Other
Eligibility
Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Kannapolis, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 13, 2016 · Synced Nov 1, 2026, 5:57 PM EST
Completed Phase 2 Interventional Results available

LIPS-B: Lung Injury Prevention Study With Budesonide and Beta

NCT01783821
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome (ARDS)
Interventions
Budesonide, Placebo, Formoterol
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
5
States / cities
Tucson, Arizona • Stanford, California • Jacksonville, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2016 · Synced Nov 1, 2026, 5:57 PM EST
Completed Phase 4 Interventional Results available

Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)

NCT02216214
View directory record Official record
Conditions
Overactive Bladder (OAB)
Interventions
Mirabegron, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
65 Years and older
Enrollment
888 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
103
States / cities
Huntsville, Alabama • Mobile, Alabama • Anchorage, Alaska + 88 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2024 · Synced Nov 1, 2026, 5:57 PM EST
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Risperidone in Situ Microparticle (ISM)® in Patients With Acute Schizophrenia

NCT03160521
View directory record Official record
Conditions
Acute Schizophrenia
Interventions
Risperidone ISM 75 mg, Risperidone ISM 100 mg, Placebo of Risperidone ISM
Drug
Lead sponsor
Rovi Pharmaceuticals Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
20
States / cities
Rogers, Arkansas • Cerritos, California • Garden Grove, California + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2022 · Synced Nov 1, 2026, 5:57 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Test if SAR443809 is Tolerated and Safe When Taken as a Single Dose in Healthy Adults

NCT06326814
View directory record Official record
Conditions
Paroxysmal Nocturnal Hemoglobinuria
Interventions
Humanized anti-Factor Bb monoclonal antibody, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 45 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 22, 2024 · Synced Nov 1, 2026, 5:57 PM EST
Terminated Phase 4 Interventional Results available

HPV Vaccine Therapy in Interrupting Progression in Patients With High-Grade Vulvar or Anal Lesions

NCT03051516
View directory record Official record
Conditions
High Grade Anal Canal Intraepithelial Neoplasia, High Grade Vulvar Squamous Intraepithelial Lesion
Interventions
Laboratory Biomarker Analysis, Placebo Administration, Questionnaire Administration, Recombinant Human Papillomavirus Nonavalent Vaccine
Other · Biological
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
27 Years to 69 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
Birmingham, Alabama • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Nov 1, 2026, 5:57 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Multiple Dose Study Evaluating the Safety and Tolerability of NSA-789

NCT00795730
View directory record Official record
Conditions
Alzheimer Disease, Healthy Subjects
Interventions
NSA-789, placebo
Drug · Other
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2021 · Synced Nov 1, 2026, 5:57 PM EST
Not listed Phase 2 Interventional

Dose-Finding Study of REN-1654 in Patients With Post-Herpetic Neuralgia

NCT00099528
View directory record Official record
Conditions
Neuralgia, Shingles, Peripheral Nervous System Disease
Interventions
REN-1654
Drug
Lead sponsor
Renovis
Industry
Eligibility
55 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
16
States / cities
Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2010 · Synced Nov 1, 2026, 5:57 PM EST
Completed Phase 3 Interventional

ACCESS: A Controlled Comparison of Eritoran Tetrasodium and Placebo in Patients With Severe Sepsis

NCT00334828
View directory record Official record
Conditions
Severe Sepsis
Interventions
eritoran tetrasodium, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
69
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Nov 1, 2026, 5:57 PM EST
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Study Designed to Assess the Safety, Tolerability and PK of PTI-808 in Healthy Volunteers and in Adults With Cystic Fibrosis

NCT03251092
View directory record Official record
Conditions
Healthy Volunteer - Complete, Cystic Fibrosis - Complete
Interventions
PTI-808, Placebo, PTI-428, PTI-801
Drug
Lead sponsor
Proteostasis Therapeutics, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
179 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
22
States / cities
Tucson, Arizona • Stanford, California • Denver, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2020 · Synced Nov 1, 2026, 5:57 PM EST
Completed Phase 2 Interventional Results available

Efficacy and Safety of ETX-018810 for the Treatment of Diabetic Peripheral Neuropathic Pain

NCT04688671
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain, Diabetic Peripheral Neuropathy
Interventions
ETX-018810, Placebo
Drug
Lead sponsor
Eliem Therapeutics (UK) Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
22
States / cities
Mobile, Alabama • Phoenix, Arizona • Fresno, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Nov 1, 2026, 5:57 PM EST
Completed Phase 4 Interventional Results available

Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson's Disease

NCT01018264
View directory record Official record
Conditions
Overactive Bladder in Parkinson's Disease
Interventions
solifenacin succinate (VESIcare), placebo
Drug
Lead sponsor
University of South Florida
Other
Eligibility
40 Years to 80 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Miami, Florida • Tampa, Florida • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Nov 1, 2026, 5:57 PM EST
Completed Phase 1 Interventional

Safety Study of a Single Dose of REGN88(SAR153191)in Patients With Rheumatoid Arthritis

NCT01055899
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
REGN88
Biological
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Duncansville, Pennsylvania • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 30, 2013 · Synced Nov 1, 2026, 5:57 PM EST
Completed Phase 3 Interventional

Study to Evaluate the Safety of Twice Daily Oral Carvedilol

NCT00129363
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
Carvedilol
Drug
Lead sponsor
Shaddy, Robert, M.D.
Individual
Eligibility
1 Day to 17 Years
Enrollment
75 participants
Timeline
2002 – 2006
U.S. locations
17
States / cities
Los Angeles, California • Palo Alto, California • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 25, 2008 · Synced Nov 1, 2026, 5:57 PM EST